Time filter

Source Type

Alp R.,Namik Kemal University | Planci Y.,Dicle University | Yapici Z.,Istanbul University | Turk Boru U.,Dr Lutfi Kirdar Kartal Research And Education Hospital
Noropsikiyatri Arsivi | Year: 2012

Background: The prevalence rate of multiple sclerosis (MS) might differ between countries depending on whether the data is obtained from hospital-based or population-based studies. This study aimed at identifying the prevalence of MS with face-to-face interviews by door-to-door field visits in a population study conducted in the north-eastern (Caucasus) part of Turkey situated at high altitude, with long winters and with inhabitants having low socio-economical status. Method: In this cross-sectional field study, one of every three houses within the city proper were visited searching for MS cases. Results: 7249 subjects were included in face-to-face interviews. Five patients diagnosed as having MS were identified. The prevalence of MS was calculated as 68.97/100000, with a mean age of 35.1±10.2 years and female to male ratio of 4/1. Conclusion: This study, similar to the previous population-based study conducted in our country, demonstrated that the prevalence of MS in Turkey could be higher than expected. © Archives of Neuropsychiatry, published by Galenos Publishing.

Alkis N.,Dr Abdurrahman Yurtaslan Research And Education Hospital | Demirci U.,Gazi University | Benekli M.,Gazi University | Yilmaz U.,Dokuz Eylul University | And 9 more authors.
Journal of B.U.ON. | Year: 2011

Purpose: To retrospectively evaluate the efficacy and tolerability of mitomycin-C (MMC) in combination with fluoropyrimidines as salvage 3rd -or 4th-line therapy in metastatic colorectal cancer (MCRC) patients. Methods: All patients in this study had previously failed oxaliplatin and irinotecan-based chemotherapy. Patients were treated with MMC (6 mg/m2 intravenously/i.v.) on day 1 in combination with either oral UFT (500 mg/m 2) and oral leucovorin (LV) (30mg) on days 1-14 every 3 weeks (group A) or infusional 5-fluorouracil (5-FU) by deGramont regimen with i.v. LV (200 mg/m2) on days 1 and 2, every 2 weeks (group B). Results: Thirty-nine MCRC patients were analyzed. Twenty-two of them were in group A and 17 in group B. Thirty-three were evaluable for clinical efficacy. The clinical benefit in the intent-to-treat (ITT) population was 30.8%. Median progression free survival (PFS) was 6 months (95% confidence interval/CI 4-8) and median overall survival (OS) 9 months (95% CI 6.5-11.5). Median PFS was 3 months (95% CI 2.4-3.6) in group A and 7 months (95% CI 5.1-8.9) in group B (p=0.009). Median OS was 7 months (95% CI 4.3-9.7) in group A and 12 months (95% CI 5.4-18.6) in group B (p=0.422). The combination of MMC and fluoropyrimidines was generally well tolerated. The most common severe toxicities were nausea and vomiting, neutropenia, hepatotoxicity and diarrhea. Conclusion: MMC in combination with fluoropyrimidines is safe and active in heavily-pretreated MCRC patients. This combination remains a viable option in these patients. However, better therapies are urgently needed. © 2011 Zerbinis Medical Publications.

Discover hidden collaborations